Cancer Protein Description
This report provides a detailed description of a selected cancer protein with information collected from various sources, including UniProt, the Wellcome Trust Sanger Institute’s Catalogue of Somatic Mutations in Cancer (COSMIC), and the Atlas of Genetics and Cytogenetics in Oncology and Haematology.
| Protein Name: | CDK4 |
| Gene Name: | CDK4 |
| Protein Full Name: | Cell division protein kinase 4 |
| Alias: | CRK3; Cyclin-dependent kinase 4; EC 2.7.11.22; Kinase Cdk4; PSK-J3 |
| Mass (Da): | 33730 |
| Number AA: | 303 |
| UniProt ID: | P11802 |
| Locus ID: | 1019 |
| COSMIC ID: | CDK4 |
| Gene location on chromosome: | 12q14.1 |
| Cancer protein type: | OP |
| Effect of cancer mutation on protein: | GAIN |
| Effect of active protein on cancer: | PROMOTES |
| Number of cancer specimens: | 21422 |
| Percent of cancer specimens with mutations: | 0.23 |
| Found in amplified chromosomal regions in human cancers: | Sarcomas (40%); malignant melanomas; gliomas |
| Normal role description: | CDK4 is a protein-serine/threonine kinase, and a part of the protein kinase complex important for cell cycle G1 phase progression. Its activity is restricted to the G1-S phase. CDK4 is responsible for the phosphorylation of retinoblastoma gene product (Rb) and mutations in this gene as well as in its related proteins including D-type cyclins, p16(INK4a) and Rb were all found to be associated with tumorigenesis of a variety of cancers, such as cutaneous malignant melanoma type 3 (CMM3) and |
| Commentary on involvement of protein in cancer: | 1/201 breast cancer samples; 1/477 CNS samples; and 1/359 lung cancer samples were found to be mutated (mis-sense and silent) in Sanger COSMIC |